发布时间: 2026 - 10 - 20
In the past, the industry competed on scale, deal count, and star cases. Now, LP concerns are returning to three of the most fundamental questions: How much has been deployed? What remains on the books? How much has actually been returned?As the industry shifts from incremental expansion to stock management and the exit cycle, fund performance can no longer be proven by stories alone; it requires a ruler that can be publicly benchmarked and tracked over the long term.Recently, LP Consultant officially released the LP Consultant RMB Fund Performance Benchmark (2026)(hereinafter referred to as t...
浏览次数:1
发布时间: 2026 - 10 - 14
On October 14, according to the latest List of Drug Master Files (DMFs) 3rd Quarter 2026published by the U.S. Food and Drug Administration (FDA), the JiaLin® Germanium-Gallium Generator independently developed by Chengdu New Radiomedicine Technology Co., Ltd. has officially completed its Drug Master File (DMF) filing, with the status marked as Active and DMF number 44330.Completion of an FDA DMF filing is a prerequisite for pharmaceutical companies (NDA/ANDA/IND applicants) to reference an upstream product. Currently, only four Germanium-Gallium Generators have completed FDA DMF filings a...
浏览次数:2
发布时间: 2026 - 10 - 05
At approximately 17:30 Beijing Time on October 5, 2026, the 2026 Nobel Prize in Physiology or Medicine was announced.The 2026 Nobel Prize in Physiology or Medicine was awarded to Karl Deisseroth, Peter Hegemann, and Georg Nagel for their "discoveries concerning light-controlled ion channels and optogenetics."It is understood that the Nobel Foundation announced in September that the prize amount for each award in 2026 would be increased from the previous 11 million Swedish kronor (approximately 7.34 million RMB) to 12 million Swedish kronor (approximately 8.01 million RMB), an increas...
浏览次数:5
发布时间: 2026 - 09 - 30
In September 2026, the Ministry of Industry and Information Technology and nine other departments jointly issued the "15th Five-Year Plan for the Development of the Pharmaceutical Industry." The plan proposes that by 2030, biopharmaceutical R&D and application should rank among the world's top, the effectiveness of innovation-driven development should be fully unleashed, and systematic breakthroughs should be achieved in key core technologies in key fields. Core competitiveness and international influence will jump significantly. The biopharmaceutical industry will accele...
浏览次数:8
共144条页次1/36首页PREV12345678910...NEXTlast page
Address: 505 China Resources Building, 2666 Keyuan South Road, Nanshan District, Shenzhen
TEL:0755-8831-6141
E-mail:info@efungcapital.com
Copyright ©2018 - 2021 Shenzhen Efung Investment Management Co. Ltd.
Rhino Cloud provides enterprise cloud services
犀牛云提供云计算服务